Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. Observations: A 68-year-old man...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993622002055 |
| _version_ | 1818549677282295808 |
|---|---|
| author | Matthew G. Field H. Culver Boldt Taher Abu Hejleh Elaine M. Binkley |
| author_facet | Matthew G. Field H. Culver Boldt Taher Abu Hejleh Elaine M. Binkley |
| author_sort | Matthew G. Field |
| collection | DOAJ |
| description | Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. Observations: A 68-year-old man presented with an amelanotic choroidal lesion in the left eye concerning for choroidal metastasis. Systemic evaluation identified widely metastatic adenocarcinoma of the lung with EGFR exon 19 mutation. Within one month of initiating treatment with osimertinib, there was complete resolution of the subretinal fluid over the choroidal lesion and decreased thickness of the lesion. At follow-up after three months of treatment, the lesion was clinically involuted. Positron emission tomography at two months and magnetic resonance imaging of the brain at three months showed significant interval decrease in size and activity of the primary right lung lesion, central nervous system lesions, and other metastatic sites with no new metastatic lesions. After 17 months of follow up, the lesion remained involuted. Conclusions and Importance: Osimertinib may be considered as a first-line treatment option in patients with choroidal metastases from an EGFR-mutated non-small cell lung cancer. |
| first_indexed | 2024-12-12T08:36:28Z |
| format | Article |
| id | doaj.art-f041cd29518b4dc19e08bf98dcc3f3ac |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-12-12T08:36:28Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-f041cd29518b4dc19e08bf98dcc3f3ac2022-12-22T00:30:56ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362022-06-0126101459Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancerMatthew G. Field0H. Culver Boldt1Taher Abu Hejleh2Elaine M. Binkley3Department of Ophthalmology and Visual Science, University of Iowa Hospitals and Clinics, Iowa City, IA, USADepartment of Ophthalmology and Visual Science, University of Iowa Hospitals and Clinics, Iowa City, IA, USADivision of Hematology, Oncology, Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USADepartment of Ophthalmology and Visual Science, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; Corresponding author. Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA.Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. Observations: A 68-year-old man presented with an amelanotic choroidal lesion in the left eye concerning for choroidal metastasis. Systemic evaluation identified widely metastatic adenocarcinoma of the lung with EGFR exon 19 mutation. Within one month of initiating treatment with osimertinib, there was complete resolution of the subretinal fluid over the choroidal lesion and decreased thickness of the lesion. At follow-up after three months of treatment, the lesion was clinically involuted. Positron emission tomography at two months and magnetic resonance imaging of the brain at three months showed significant interval decrease in size and activity of the primary right lung lesion, central nervous system lesions, and other metastatic sites with no new metastatic lesions. After 17 months of follow up, the lesion remained involuted. Conclusions and Importance: Osimertinib may be considered as a first-line treatment option in patients with choroidal metastases from an EGFR-mutated non-small cell lung cancer.http://www.sciencedirect.com/science/article/pii/S2451993622002055Choroidal metastasisEpidermal growth factor receptorEGFRLung adenocarcinomaOsimertinibTyrosine kinase inhibitor |
| spellingShingle | Matthew G. Field H. Culver Boldt Taher Abu Hejleh Elaine M. Binkley Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer American Journal of Ophthalmology Case Reports Choroidal metastasis Epidermal growth factor receptor EGFR Lung adenocarcinoma Osimertinib Tyrosine kinase inhibitor |
| title | Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer |
| title_full | Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer |
| title_fullStr | Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer |
| title_full_unstemmed | Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer |
| title_short | Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer |
| title_sort | successful response to first line treatment with osimertinib for choroidal metastasis from egfr mutated non small cell lung cancer |
| topic | Choroidal metastasis Epidermal growth factor receptor EGFR Lung adenocarcinoma Osimertinib Tyrosine kinase inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S2451993622002055 |
| work_keys_str_mv | AT matthewgfield successfulresponsetofirstlinetreatmentwithosimertinibforchoroidalmetastasisfromegfrmutatednonsmallcelllungcancer AT hculverboldt successfulresponsetofirstlinetreatmentwithosimertinibforchoroidalmetastasisfromegfrmutatednonsmallcelllungcancer AT taherabuhejleh successfulresponsetofirstlinetreatmentwithosimertinibforchoroidalmetastasisfromegfrmutatednonsmallcelllungcancer AT elainembinkley successfulresponsetofirstlinetreatmentwithosimertinibforchoroidalmetastasisfromegfrmutatednonsmallcelllungcancer |